Constellation Brands Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Constellation Brands (STZ) is scheduled to report Q2 earnings on October 6, with analysts forecasting a decline in EPS to $3.41 from $4.32 year-over-year and revenue of $2.48 billion, down from $2.92 billion. This downward revision follows the company's September 2 cut to its fiscal year 2026 outlook, citing macroeconomic headwinds, which has prompted several analyst downgrades and price target reductions from firms including Barclays and Wells Fargo, contributing to a 1.3% share price drop.

Analysis

Constellation Brands (STZ) is facing significant headwinds ahead of its second-quarter earnings release on October 6. Consensus expectations point to a sharp year-over-year decline, with quarterly earnings projected at $3.41 per share, down from $4.32, and revenue anticipated to fall to $2.48 billion from $2.92 billion. This negative outlook is underpinned by the company's own guidance revision on September 2, when it cut its fiscal year 2026 forecast, citing macroeconomic pressures on consumer demand. The market and analyst community have reacted bearishly; the stock recently fell 1.3% to $134.67, and a wave of analyst revisions has followed. Notably, Barclays downgraded the stock from Overweight to Equal-Weight, while all surveyed analysts, including those from Wells Fargo, BMO Capital, and Morgan Stanley, have materially cut their price targets. These new targets, while still mostly above the current price, reflect a broad-based recalibration of expectations for the company's performance.

Key Decisions for Investors

• Given the company's recent guidance cut and the subsequent negative analyst revisions, investors should be prepared for weak Q2 results and exercise caution, as any further negative surprises on consumer demand could pressure the stock further.
• The primary focus for the upcoming earnings call should be on management's forward-looking commentary regarding the severity and duration of the cited macroeconomic headwinds, rather than the backward-looking quarterly results.
• With the stock trading at $134.67 and revised analyst price targets now ranging from $150 to $190, a key consideration is whether the current valuation sufficiently prices in the lowered growth expectations or if risks of further downward revisions remain.
• Note the downgrade from Barclays to Equal-Weight with a $150 price target, which suggests that some sell-side analysts see limited upside potential from the current trading levels in the near term.